CA2075517A1 - Transdermal patch incorporating a polymer film incorporated with an active agent - Google Patents

Transdermal patch incorporating a polymer film incorporated with an active agent

Info

Publication number
CA2075517A1
CA2075517A1 CA2075517A CA2075517A CA2075517A1 CA 2075517 A1 CA2075517 A1 CA 2075517A1 CA 2075517 A CA2075517 A CA 2075517A CA 2075517 A CA2075517 A CA 2075517A CA 2075517 A1 CA2075517 A1 CA 2075517A1
Authority
CA
Canada
Prior art keywords
active ingredient
melt
active agent
matrix polymer
carrier layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2075517A
Other languages
French (fr)
Other versions
CA2075517C (en
Inventor
John Wick
Ludwig J. Weimann
Wayne C. Pollock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MLI Acquisition Corp II
Original Assignee
MLI Acquisition Corp II
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MLI Acquisition Corp II filed Critical MLI Acquisition Corp II
Publication of CA2075517A1 publication Critical patent/CA2075517A1/en
Application granted granted Critical
Publication of CA2075517C publication Critical patent/CA2075517C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

Devices for the controlled release of an active agent to the skin or mucosa of a host are disclosed, which devices are laminates of a backing layer, a monolithic carrier layer of an active ingredient selected from active agent, active agent enhancers and mixtures thereof, melt-blended with a thermoplastic matrix polymer capable of controllably releasing the active ingredient, wherein the active ingredient is heat stable at the melt temperature of the matrix polymer, together with means for affixing the laminate to the skin or mucosa of the host so that the active ingredient is continuously released from the carrier layer thereto. Methods for assembling the device are also disclosed, in which a thermoplastic matrix polymer capable of controllably releasing an active ingredient is melt-blended with an active ingredient that is heat stable at the melt temperature of the matrix polymer, so that a melt-blend of the active ingredient and the thermoplastic matrix polymer is formed, which melt-blend is formed into a monolithic carrier layer, and the carrier layer is then combined with a backing layer and means for affixing the laminate to the skin or mucosa of the host so that the active ingredient is released from the carrier layer thereto.
CA002075517A 1992-04-01 1992-08-07 Transdermal patch incorporating a polymer film incorporated with an active agent Expired - Lifetime CA2075517C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86153492A 1992-04-01 1992-04-01
US07/861,534 1992-04-01

Publications (2)

Publication Number Publication Date
CA2075517A1 true CA2075517A1 (en) 1993-10-02
CA2075517C CA2075517C (en) 1997-03-11

Family

ID=25336076

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002075517A Expired - Lifetime CA2075517C (en) 1992-04-01 1992-08-07 Transdermal patch incorporating a polymer film incorporated with an active agent

Country Status (10)

Country Link
US (3) US5662926A (en)
EP (1) EP0563507B1 (en)
JP (1) JP3354185B2 (en)
KR (1) KR960005143B1 (en)
AT (1) ATE166574T1 (en)
BR (1) BR9203172A (en)
CA (1) CA2075517C (en)
DE (1) DE69225695T2 (en)
ES (1) ES2118124T3 (en)
MX (1) MX9206090A (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6131575A (en) * 1991-01-10 2000-10-17 The Procter & Gamble Company Urinary incontinence device
WO1996000072A1 (en) * 1994-06-23 1996-01-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
DE19517145C2 (en) * 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermal therapeutic system (TTS) for administration of testosterone
US6245347B1 (en) * 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
DE19649534B4 (en) 1996-11-29 2004-05-06 Lts Lohmann Therapie-Systeme Ag Packing made of composite packaging for packaging active ingredient-containing patches
JP2001517216A (en) * 1997-02-28 2001-10-02 ミネソタ マイニング アンド マニュファクチャリング カンパニー Transdermal devices for testosterone delivery
US5953885A (en) * 1997-04-08 1999-09-21 Retail Communications Corp. Cosmetic sampler and method of making using bulk thin film application techniques
US6691872B1 (en) 1997-04-08 2004-02-17 Aki, Inc. Method of making a cosmetic sampler using bulk thin film application techniques
US6261405B1 (en) 1997-06-27 2001-07-17 Noven Pharmaceuticals, Inc. Method and apparatus for making a patch
DE19728516C2 (en) * 1997-07-04 1999-11-11 Sanol Arznei Schwarz Gmbh TTS for administration of levonorgestrel and possibly estradiol
DE19728517C2 (en) * 1997-07-04 1999-11-11 Sanol Arznei Schwarz Gmbh TTS for the administration of sex steroid hormones and process for its preparation
US6767902B2 (en) 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
US20020012694A1 (en) * 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
EP1061802B1 (en) 1997-12-19 2004-07-28 Taro Pharmaceuticals U.S.A., Inc. Topical carbamazepine formulations and methods of use
US7491232B2 (en) * 1998-09-18 2009-02-17 Aptus Endosystems, Inc. Catheter-based fastener implantation apparatus and methods with implantation force resolution
DE19821788C1 (en) * 1998-05-15 1999-12-02 Sanol Arznei Schwarz Gmbh Transdermal therapeutic system (TTS) containing pergolide
WO2000018339A1 (en) * 1998-09-29 2000-04-06 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US6475514B1 (en) 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
PL195871B1 (en) 1998-12-18 2007-11-30 Alza Corp Transparent transdermal nicotine delivery devices
US6270781B1 (en) 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6274168B1 (en) * 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
AU3932600A (en) * 1999-04-01 2000-10-23 Alza Corporation Transdermal drug delivery devices comprising a polyurethane drug reservoir
US6417227B1 (en) 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
WO2000076485A1 (en) * 1999-06-11 2000-12-21 Lintec Corporation Moisture-sensitive preparation of percutaneous absorption type
FR2795326B1 (en) * 1999-06-28 2001-08-31 Adir SOLID THERMOFORMABLE PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE
DE10001546A1 (en) * 2000-01-14 2001-07-19 Beiersdorf Ag Process for the continuous production and coating of self-adhesive compositions based on polyisobutylene with at least one active pharmaceutical ingredient
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
DE10018834A1 (en) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermal or transmucosal pharmaceutical dosage form for treatment of nicotine dependence or smoking withdrawal contains nicotine compound or substitute and CNS active compound
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
KR100860822B1 (en) * 2000-12-21 2008-09-30 주식회사 엘지생활건강 Patch having sterilizing and disinfective power and for decomposition
DE10110391A1 (en) 2001-03-03 2002-09-26 Lohmann Therapie Syst Lts Highly flexible nicotine transdermal therapeutic system with nicotine as active ingredient
US20030176379A1 (en) * 2001-05-11 2003-09-18 Raoof Araz A. Antisense permeation enhancers
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
US20030014947A1 (en) * 2001-07-19 2003-01-23 Sarojini Deevi Laminated metal foil packaging material and method of making
IL160928A0 (en) * 2001-10-19 2004-08-31 Maxim Pharm Inc Use of histamine to treat liver disease
CN1578650A (en) * 2001-11-06 2005-02-09 马克西姆医药公司 Compositions for the treatment of infectious diseases
WO2003090855A1 (en) * 2002-04-25 2003-11-06 Centre Pharmapeptides Apparatus and assembly for administering antimicrobial agent
AR033748A1 (en) * 2002-05-15 2004-01-07 Thalas Group Inc A DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE SUBSTANCES THAT INCLUDES TWO SUPERPOSED ADHESIVE LAYERS AND A PROCEDURE TO PREPARE IT
DE10317692A1 (en) 2003-04-17 2004-11-11 Lts Lohmann Therapie-Systeme Ag Medical active substance patches with reduced optical conspicuity on the skin
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US8524272B2 (en) * 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
US20050037194A1 (en) * 2003-08-15 2005-02-17 Kimberly-Clark Worldwide, Inc. Thermoplastic polymers with thermally reversible and non-reversible linkages, and articles using same
WO2005032340A2 (en) * 2003-09-29 2005-04-14 Secant Medical, Llc Integral support stent graft assembly
CN100457064C (en) * 2003-10-28 2009-02-04 诺芬药品公司 Transdermal drug delivery systems
US20050171192A1 (en) * 2003-12-11 2005-08-04 Gehlsen Kurt R. Use of histamine to treat bone disease
CA2561310C (en) † 2004-03-26 2013-04-23 Csp Technologies, Inc. Active film adhered to flexible packages and method thereof
US20050221036A1 (en) * 2004-04-01 2005-10-06 The Coca-Cola Company Polyester composition with enhanced gas barrier, articles made therewith, and methods
AU2005245407B9 (en) * 2004-05-12 2010-10-14 E.I. Dupont De Nemours And Company Films comprising a liquid-absorbant inner layer, an antimicrobial material and an impermeable outer layer
WO2006009975A2 (en) * 2004-06-22 2006-01-26 Maxim Pharmaceuticals, Inc. Histamine to treat disorders affecting muscle function
US20060252786A1 (en) * 2004-10-21 2006-11-09 The Trustees Of Columbia University Nicotinic-opioid synergy for analgesia
WO2006066244A2 (en) 2004-12-17 2006-06-22 Cash Alan B Method for extending lifespan and delaying the onset of age-related disease
US8545952B2 (en) * 2005-06-07 2013-10-01 The Coca-Cola Company Polyester container with enhanced gas barrier and method
US7820258B2 (en) * 2005-10-05 2010-10-26 The Coca-Cola Company Container and composition for enhanced gas barrier properties
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
DE102006026060B4 (en) * 2006-01-12 2013-01-31 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing as active ingredient nicotine and method for producing such systems
US7740879B2 (en) * 2006-01-17 2010-06-22 Harrogate Holdings Abuse resistant transdermal drug delivery patch
NZ572207A (en) 2006-03-24 2012-02-24 Auxilium Int Holdings Inc Stabilized compositions containing alkaline labile drugs
WO2007112285A2 (en) 2006-03-24 2007-10-04 Auxilium Pharmaceuticals, Inc. Process for the preparation of a hot-melt extruded laminate
GB2438926A (en) * 2006-06-07 2007-12-12 Paul Marshall Transdermal patch
US8124202B2 (en) * 2006-09-15 2012-02-28 The Coca-Cola Company Multilayer container for enhanced gas barrier properties
US7790077B2 (en) * 2006-09-15 2010-09-07 The Coca-Cola Company Pressurized tooling for injection molding and method of using
DE102006050558B4 (en) * 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing norelgestromin for contraception and hormone replacement
KR100860824B1 (en) * 2007-07-25 2008-09-30 주식회사 엘지생활건강 Patch having sterilizing and disinfective power and for decomposition
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US20100221313A1 (en) * 2008-12-01 2010-09-02 Innovative Pharmaceuticals, Llc Transdermal reservoir patch
CA2757302A1 (en) * 2009-04-01 2010-10-07 Andrew Crockett Methods for treating myofascial, muscle, and/or back pain
CN102427792A (en) * 2009-05-04 2012-04-25 扎斯制药公司 Methods of treating pains associated with neuroma, nerve entrapment, and other conditions
US9186334B2 (en) 2009-05-04 2015-11-17 Nuvo Research Inc. Heat assisted lidocaine and tetracaine for transdermal analgesia
AU2010276456B2 (en) 2009-07-21 2014-07-03 Mylan Inc. Process for the continuous manufacture of a polyisobutylene based transdermal patch
KR20130073893A (en) 2010-04-13 2013-07-03 나지브 바불 Dermal pharmaceutical compositions of 1-methyl-2'-6'-pipecoloxylidide and method of use
DE102010064358A1 (en) * 2010-12-29 2012-07-05 Acino Ag Transdermal application system with protruding baking foil
FR2992325B1 (en) 2012-06-26 2015-05-22 Ab7 Innovation MULTIFUNCTIONAL POLYURETHANE MONOPOLYMERIC MULTIFUNCTION SEQUENCE MATRIX AND MANUFACTURING METHOD
EP2682113B1 (en) * 2012-07-02 2018-10-31 Luye Pharma AG Sealing laminates containing agents
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
US20170291020A1 (en) * 2016-04-12 2017-10-12 Mylan Inc. Double disk transdermal system
US10653639B2 (en) 2016-05-16 2020-05-19 Cv Sciences, Inc. Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction
EP3515428B1 (en) 2016-09-22 2023-06-07 Alan B Cash Method to alleviate the symptoms of pms
KR101892270B1 (en) * 2017-04-07 2018-08-27 주식회사 삼양사 Patch system for transdermal absorption with minimized skin irritation
CA3204220A1 (en) 2021-01-14 2022-07-21 Alan B. Cash Treatment of pathological fatigue with oxaloacetate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710191A (en) * 1985-12-16 1987-12-01 Jonergin, Inc. Therapeutic device for the administration of medicaments
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
DE3743946A1 (en) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg DEVICE FOR DELIVERING NITROGLYCERIN TO THE SKIN, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
US4839174A (en) 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4840796A (en) * 1988-04-22 1989-06-20 Dow Corning Corporation Block copolymer matrix for transdermal drug release
US4908213A (en) 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine

Also Published As

Publication number Publication date
KR960005143B1 (en) 1996-04-22
DE69225695T2 (en) 1999-01-21
BR9203172A (en) 1993-10-19
JPH06335532A (en) 1994-12-06
US5676969A (en) 1997-10-14
MX9206090A (en) 1993-10-01
ES2118124T3 (en) 1998-09-16
DE69225695D1 (en) 1998-07-02
JP3354185B2 (en) 2002-12-09
EP0563507B1 (en) 1998-05-27
US5662926A (en) 1997-09-02
US5679373A (en) 1997-10-21
KR930021198A (en) 1993-11-22
CA2075517C (en) 1997-03-11
ATE166574T1 (en) 1998-06-15
EP0563507A1 (en) 1993-10-06

Similar Documents

Publication Publication Date Title
CA2075517A1 (en) Transdermal patch incorporating a polymer film incorporated with an active agent
CA2153572A1 (en) Transdermal therapeutic system with galanthamine as active ingredient
AU3268689A (en) Transdermal monolith systems
CA2160775A1 (en) Transdermal therapeutic system containing estradiol
WO2004060447A3 (en) Transdermal delivery using encapsulated agent activated by ultrasound and/or heat
JP2000502090A (en) Method for producing transdermal patch (TTS)
NO912466L (en) PLASTICS WITH HIGH CONTENT OF SOFULIZING SUBSTANCES.
CA2145631A1 (en) Two-phase matrix for sustained release drug delivery device
CA2183083A1 (en) Drug-containing adhesive composite transdermal delivery device
NZ231908A (en) Transdermal therapeutical system comprising physostigmine in a polymer-based reservoir layer
EP0737477A4 (en) Percutaneously absorbable preparation
CA2172402A1 (en) Volatile active substance containing plaster that may be produced without solvents
WO1997004818A3 (en) Transdermal therapeutic sysgtem for administering active agents to the human body via the skin
AU674902B2 (en) Plaster for the transdermal administration of volatile, pharmaceutically active, chemically alkaline ingredients, and processs for producing the same
WO2001068060A3 (en) Stabilised oversaturated transdermal therapeutical matrix systems
CA2140468A1 (en) Percutaneous administration tape preparation
EP0285181A3 (en) Etofenamate-containing adhesive tape
CA2278639A1 (en) Transdermal or topical plaster system with a polyacrylate matrix with improved physical properties
WO1994025025A3 (en) Systems for controlled release of pilocarpine
CA2007353A1 (en) Superficial Therapeutic System Comprising an Antineoplastic Active Substance, Particularly 5-Fluorouracil
MY110391A (en) Nitroglycerin-containing patch, a process for the production and the use thereof
EP0368550A3 (en) Thermal transfer receiver
JP2577956Y2 (en) Patch bag for patch
CA2123645A1 (en) Medical adhesive tape and tape preparation
JPH08231385A (en) Substrate for percutanesouly administering agent

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry